Novavax COVID
Selected indexed studies
- Humoral and cellular immune memory to four COVID-19 vaccines. (Cell, 2022) [PMID:35764089]
- Efficacy and safety of COVID-19 vaccines. (Cochrane Database Syst Rev, 2022) [PMID:36473651]
- Novavax COVID-19 Vaccine Booster Authorized. (JAMA, 2022) [PMID:36472611]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Humoral and cellular immune memory to four COVID-19 vaccines. (2022) pubmed
- Efficacy and safety of COVID-19 vaccines. (2022) pubmed
- Novavax COVID-19 Vaccine Booster Authorized. (2022) pubmed
- Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review. (2025) pubmed
- Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373). (2024) pubmed
- Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. (2021) pubmed
- An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses. (2025) pubmed
- COVID-19 update: FDA authorizes Novavax COVID-19 vaccine. (2022) pubmed
- Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine. (2024) pubmed
- Characterising the asynchronous resurgence of common respiratory viruses following the COVID-19 pandemic. (2025) pubmed